Evidence map›Paper›PMID 42670248›Full record

ArticleAdvanced healthcare materials2026

2-Deoxyglucose Dendrimer-Enabled Niclosamide Delivery to FRβ-Expressing Macrophages Alleviates Endometriosis Progression and Associated Hyperalgesia.

Anubhav Dhull, Mingxin Shi, Madeleine E Harvey, Taylor M Page, Rishi Sharma, Kenneth John Goody, Aqib Iqbal Dar, Nash S Moawad, Vijay Kumar Sirohi, Paul S Cooke and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Anubhav Dhull *Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Mingxin Shi *School of Molecular Biosciences, Center For Reproductive Biology, Washington State University, Pullman, Washington, USA.ORCID https://orcid.org/0000-0003-3390-8827
Madeleine E Harvey *School of Molecular Biosciences, Center For Reproductive Biology, Washington State University, Pullman, Washington, USA.
Taylor M PageSchool of Molecular Biosciences, Center For Reproductive Biology, Washington State University, Pullman, Washington, USA.ORCID https://orcid.org/0009-0007-7444-6477
Rishi SharmaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Kenneth John GoodyDepartment of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington, USA.
Aqib Iqbal DarDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Nash S MoawadDepartment of Obstetrics & Gynecology, University of Florida College of Medicine, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0001-9401-4785
Vijay Kumar SirohiDepartment of Physiological Sciences, University of Florida, Gainesville, Florida, USA.
Paul S CookeDepartment of Physiological Sciences, University of Florida, Gainesville, Florida, USA.
Kanako HayashiSchool of Molecular Biosciences, Center For Reproductive Biology, Washington State University, Pullman, Washington, USA.ORCID https://orcid.org/0000-0002-5028-799X
Anjali SharmaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-0748-3001

Funding

Complex inflammatory mechanisms and therapeutic targeting in endometriosisR01HD104619 · NICHD · WASHINGTON STATE UNIVERSITY · PI HAYASHI, KANAKO · 2021 to 2025
$2.4M
NICHD NIH HHS R01 HD104619NICHD NIH HHS R01HD104619
6 · The paper itself

Abstract

Endometriosis (EuE) is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, nonhormonal therapies is urgently needed. We previously reported that niclosamide, an FDA-approved anthelmintic drug, attenuates endometriotic lesion growth. We further identified folate receptor-β (FRβ)-positive macrophages as contributors to disease progression. Significantly, niclosamide inhibits FRβ

Indexed as

dendrimerendometriosismacrophagesniclosamidenonhormonal therapy

Identifiers

PMID42670248

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.